Monitor for any licensing or partnership announcements related to Olive Cell, which would validate the CDMO business model and potentially generate revenue. The lack of a commercial agreement at this stage means the near-term financial impact is uncertain.
Price Chart
Executive Summary
BioHarvest Sciences announced that its proprietary Olive Cell composition has reached commercial readiness, completing development, commercial-scale manufacturing, and the self-affirmed GRAS process. The asset is now available for licensing through the company's CDMO business, with preliminary in-vitro data showing up to 37% reduction in lipid accumulation and up to 50% reduction in collagen type I accumulation in liver disease models. This milestone demonstrates the company's ability to advance plant-cell-derived assets from development to commercialization, but no revenue or partnership agreements have been announced.
Key Facts
- Olive Cell composition has completed development, commercial-scale manufacturing, and self-affirmed GRAS process
- Asset is ready for production at BioHarvest's GMP facility and available for CDMO licensing
- In-vitro data shows up to 37% reduction in intracellular lipid accumulation and up to 50% reduction in collagen type I accumulation
- Olive Cell is the second plant-cell-derived composition to reach commercial readiness after VINIA
- No licensing or partnership agreements have been announced yet
Financial Impact
No financial terms disclosed; potential future CDMO licensing revenue but no current revenue impact
Risk Factors
- No guarantee of entering into licensing, partnership, or commercial agreements for Olive Cell
- Preliminary in-vitro findings may not translate to human clinical outcomes
- Self-affirmed GRAS does not constitute FDA approval or establish efficacy for any disease condition
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001723464-26-000060 |
| Document: bhsc_6k.htm | 0001723464-26-000060 |
| Document: 0001723464-26-000060-index-headers.html | 0001723464-26-000060 |
| Document: 0001723464-26-000060-index.html | 0001723464-26-000060 |
| Document: 0001723464-26-000060.txt | 0001723464-26-000060 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | 6-K | $1.75 $1.67 | ▼ −4.18% | ▼ −4.64% | $1.70 (−2.58%) |
Oct 8, 2026 19d ago | 6-K | $1.50 $1.70 | ▲ +13.71% | ▲ +13.99% | $1.70 (+13.71%) |
Sep 15, 2026 5w ago | 6-K | $1.66 $1.46 | ▼ −12.05% | ▼ −14.61% | $1.70 (+2.41%) |
Sep 14, 2026 6w ago | 6-K | $1.78 $1.51 | ▼ −14.93% | ▼ −17.04% | $1.70 (−4.23%) |
Jul 15, 2026 14w ago | 6-K | $2.85 $2.18 | ▼ −23.51% | ▼ −22.53% | $1.70 (−40.35%) |
Jun 18, 2026 18w ago | 6-K | $3.26 $2.75 | ▼ −15.64% | ▼ −13.98% | $1.70 (−47.85%) |
May 28, 2026 21w ago | 6-K | $3.90 $3.56 | ▼ −8.72% | ▼ −8.67% | $1.70 (−56.41%) |
May 14, 2026 23w ago | 6-K | $4.16 $3.82 | ▼ −8.17% | ▼ −7.46% | $1.70 (−59.13%) |
May 14, 2026 23w ago | 6-K | $4.16 $3.82 | ▲ +8.17% | ▲ +7.46% | $1.70 (+59.13%) |
May 14, 2026 23w ago | 6-K | $4.16 $3.82 | ▼ −8.17% | ▼ −7.46% | $1.70 (−59.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers